The results from an ongoing Phase IIa clinical trial with an allogeneic bone cell therapy, ALLOB, are keenly awaited by Gosselies, Belgium-based biotech Bone Therapeutics SA, which may eventually have to look at further financing options to progress its cell therapy platform.
Top-line Phase IIa results are expected in mid-2019 with the "off-the-shelf" bone cell therapy, ALLOB, in 32 patients undergoing spinal fusion procedures, Bone Therapeutics said on Jan. 22
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?